The hemoglobin, albumin, lymphocyte, and platelet (HALP) score can help to guide treatment decisions in patients living with ...

Explore the latest advancements in immunotherapies for T-cell lymphoma, addressing unique challenges and promising new treatment options.

Results from the Phase III KEYNOTE-689 trial show that adding perioperative Keytruda (pembrolizumab) to standard-of-care ...

Blood cancer, which originates from irregular blood cell generation within the bone marrow, represents a serious health ...

Volumetric PET biomarkers may help predict risk of toxicity from CAR T-cell therapy in patients with large B-cell lymphoma, ...

Waldenstrom Macroglobulinemia sees growing innovation as next-gen BTK inhibitors and novel therapies aim to overcome resistance and reshape treatment pathways. BTK inhibitors laid the groundwork, but ...

Follicular lymphoma -- typically a slow-growing or indolent form of non-Hodgkin lymphoma that arises from B lymphocytes -- ...

Physician-scientists at Memorial Sloan Kettering Cancer Center (MSK) recently published two papers that advance the science of addressing critical issues with CAR T cell therapy in patients with ...

Unlike Hodgkin lymphoma, the non-Hodgkin varieties look different under the microscope and don’t contain Reed-Sternberg cells. T-cell lymphoma is a type of non-Hodgkin lymphoma.

SAN DIEGO — Treatment with axicabtagene ciloleucel conferred durable benefit to patients with relapsed or refractory indolent B-cell non-Hodgkin lymphoma, according to study results presented at ...